With this notice, Frontiers states its awareness of serious allegations surrounding the article “Topical Ophthalmic Formulation of Trichostatin A and SurR9-C84A for Quick Recovery Post-alkali Burn of Corneal Haze” published on 5 May 2017. Our Chief Editors will direct an investigation in full accordance with our procedures. The situation will be updated as soon as the investigation is complete.
. 2017 Jun 28;8:427. doi: 10.3389/fphar.2017.00427
Expression of Concern: Topical Ophthalmic Formulation of Trichostatin A and SurR9-C84A for Quick Recovery Post-alkali Burn of Corneal Haze
Frontiers Editorial Office*
Edited and reviewed by: Théophile Godfraind, Université Catholique de Louvain, Belgium
✉
*Correspondence: Frontiers Editorial Office editorial.office@frontiersin.org
This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology
Received 2017 Jun 14; Accepted 2017 Jun 14; Collection date 2017.
Copyright © 2017 Frontiers Editorial Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
PMCID: PMC5487523 PMID: 28659808
This is an expression of concern about the following article: "Topical Ophthalmic Formulation of Trichostatin A and SurR9-C84A for Quick Recovery Post-alkali Burn of Corneal Haze", 223.